Regul Pept 181:5066 Boban Blagaic A, Blagaic V, Mirt M et al (2005) Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats
Some individuals respond remarkably while others experience modest benefits
Users generally take it to possibly help with glaucoma, cataracts, asthma, heart disease, liver disease, hepatitis, Alzheimers, memory loss, Parkinsons and osteoarthritis
Obesity and Weight Management Research The primary focus of cagrilintide research has been its profound effects on body weight reduction [9] : Key Clinical Trial Data - Phase 2 ONWARDS 1 Design: 32-week, dose-ranging study in 706 adults with overweight/obesity Results (Cagrilintide monotherapy): [9] 0.3 mg weekly: -3.9% weight loss 0.6 mg weekly: -6.0% weight loss 1.2 mg weekly: -8.1% weight loss 2.4 mg weekly: -10.8% weight loss 4.5 mg weekly: -10.4% weight loss Mechanism: Weight loss attributed primarily to reduced energy intake (-535 kcal/day at 2.4 mg dose) rather than increased energy expenditure Research Implications: Cagrilintide provides a valuable research tool for investigating amylin receptor-mediated satiety pathways independent of GLP-1 signaling, offering insights into hormone-specific contributions to appetite regulation
Using unregulated research-grade powders purchased online carries risks including unknown potency, contamination, and no medical supervision for dosing or monitoring
